ClinicalTrials.gg
CompletedNCT06685185Updated Apr 9, 2026

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

A Phase 1 interventional study of NNC0363-1063 and Placebo in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Enrollment
53rd of 149
117 · median 62
Started
2024
with 1 other
Phase 1
74 of 226
1 open now
Registered
218th of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 53rd largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2024, is one of 74 in phase 1, and was the 218th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 3½ to 8½ weeks. Part 3 is a meal test multiple dose study part conducted in participants with T1D and will last for 7 to 11 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1A SAD (healthy participants)

  • Male or female of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Age 18-64 years (both inclusive) at the time of signing the .
  • between 18.5-29.9 kilogram per square metre( kg/m\^2) (both inclusive) at the day of screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)

  • Male or female of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Age 18-64 years (both inclusive) at the time of signing the informed consent.
  • Body mass index between 18.5-29.9 kg/m\^2 (both inclusive) at the day of screening.
  • Diagnosed with type 1 diabetes mellitus greater than or equal to( ≥)1 year prior to the day of screening.
  • Considered to be generally healthy (except for mild conditions under stable treatment associated with type 1 diabetes mellitus) based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

Part 1A SAD (healthy participants)

  • Male of reproductive age who, or whose female partner(s), is not using an adequate method.
  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)

  • Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.
  • Any condition, except for mild conditions under stable treatment associated with type 1 diabetes mellitus, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Part 1A: SAD: NNC0363-1063

    Participants will receive single dose of NNC0363-1063 subcutaneously.

    Drug: NNC0363-1063

  • Placebo comparator
    Part 1A: SAD: Placebo

    Participants will receive NNC0363-1063 matching placebo subcutaneously.

    Drug: Placebo

  • Experimental
    Part 1B: SAD: NNC0363-1063

    Participants will receive NNC0363-1063 subcutaneously.

    Drug: NNC0363-1063

  • Active comparator
    Part 1B: SAD: Insulin degludec

    Participants will receive insulin degludec subcutaneously.

    Drug: Insulin degludec

  • Experimental
    Part 2: PoP: NNC0363-1063

    Participants will receive NNC0363-1063 subcutaneously.

    Drug: NNC0363-1063

  • Experimental
    Part 3 Meal test: NNC0363-1063

    Participants will receive NNC0363-1063 subcutaneously.

    Drug: NNC0363-1063

  • Active comparator
    Part 3 Meal test: Insulin detemir

    Participants will receive insulin detemir subcutaneously.

    Drug: Insulin detemir

Interventions

  • DrugNNC0363-1063

    NNC0363-1063 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

  • Insulin degludec will be administered subcutaneously.

    Also known as: Tresiba

  • Insulin detemir will be administered subcutaneously.

    Also known as: Levemir

06

What researchers measure

Primary outcomes

  1. Part 1 SAD: Number of adverse events

    Measured in number of events.

    Time frame: From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)

  2. Part 2 PoP: CL/F,I1063,SD- Apparent serum clearance of NNC0363-1063 after a single dose

    Measured in millilitre per hour\*kilogram (mL/\[h\*kg\]).

    Time frame: From IMP administration at day 1 up to 7 days

  3. Part 3 Meal test: AUC,PG,meal: Area under the plasma glucose concentration-time curve at steady state

    Measured in hours\*millimoles per litre (h\*mmol/L).

    Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test

Secondary outcomes

  1. Part 1 SAD: Number of hypoglycaemic episodes

    Measured in number of episodes.

    Time frame: From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)

  2. Part 1 SAD: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose

    Measured in hours\*picomoles per litre (h\*pmol/L).

    Time frame: Up to 7 days

  3. Part 1 SAD: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose

    Measured in h\*pmol/L.

    Time frame: Up to 2 days

  4. Part 1 SAD: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose

    Measured in picomoles per litre (pmol/L).

    Time frame: Up to 7 days

  5. Part 2 PoP: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose

    Measured in h\*pmol/L.

    Time frame: Up to 7 days

  6. Part 2 PoP: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose

    Measured in h\*pmol/L.

    Time frame: Up to 2 days

  7. Part 2 PoP: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose

    Measured in pmol/L.

    Time frame: Up to 7 days

  8. Part 3 Meal test: AUC0-1h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 1 hour after initiation of the meal test at steady state

    Measured in h\*mmol/L.

    Time frame: From 0 hours to 1 hour after initiation of the meal test (day 2 of visit 2 and visit 3)

  9. Part 3 Meal test: AUC0-2h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 2 hours after initiation of the meal test at steady state

    Measured in h\*mmol/L.

    Time frame: From 0 hours to 2 hours after initiation of the meal test (day 2 of visit 2 and visit 3)

  10. Part 3 Meal test: AUC0-4h,PG,mean: Area under the plasma glucose concentration-time curve from 0 to 4 hours after initiation of the meal test at steady state

    Measured in h\*mmol/L.

    Time frame: From 0 hours to 4 hours after initiation of the meal test (day 2 of visit 2 and visit 3)

  11. Part 3 Meal test: AUC0-6h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 6 hours after initiation of the meal test at steady state

    Measured in h\*mmol/L.

    Time frame: From 0 hours to 6 hours after initiation of the meal test (day 2 of visit 2 and visit 3)

  12. Part 3 Meal test: PGmax,meal: Maximum observed plasma glucose concentration at steady state

    Measured in millimoles per litre (mmol/L).

    Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test

  13. Part 3 Meal test: tPGmax,meal: Time to maximum observed plasma glucose concentration from at steady state

    Measured in hours.

    Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test

  14. Part 3 Meal test: ΔPGav,0-1h,meal: Mean change in plasma glucose from 0 to 1 hour after initiation of the meal test at steady state

    Measured in mmol/L.

    Time frame: From 0 hours to 1 hour after initiation of the meal test (day 2 of visit 2 and visit 3)

  15. Part 3 Meal test: ΔPGav,0-2h,meal: Mean change in plasma glucose from 0 to 2 hours after initiation of the meal test at steady state

    Measured in mmol/L.

    Time frame: From 0 hours to 2 hours after initiation of the meal test (day 2 of visit 2 and visit 3)

  16. Part 3 Meal test: AUCτ,I1063,SS: Area under the serum NNC0363-1063 concentration-time curve during one dosing interval at steady state

    Measured in h\*pmol/L.

    Time frame: At day 2 of visit 2 and visit 3 after last IMP administration

  17. Part 3 Meal test: Cmax,I1063,SS: Maximum observed serum NNC0363-1063 concentration during one dosing interval at steady state

    Measured in pmol/L.

    Time frame: At day 2 of visit 2 and visit 3 after last IMP administration

  18. Part 3 Meal test: Number of adverse events

    Measured in number of events.

    Time frame: From first IMP administration (day 1 of visit 2 and visit 3) until 24 hours after last IMP administration (day 2 of visit 2 and visit 3)

  19. Part 3 Meal test: Number of hypoglycaemic episodes

    Measured in number of episodes.

    Time frame: From first IMP administration (day 1 of visit 2 and visit 3) until 24 hours after last IMP administration (day 2 of visit 2 and visit 3)

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Mar 2026, 15 months.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 15 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2024
First posted
Nov 12, 2024
StartActual
Nov 12, 2024
Primary completionActual
Mar 8, 2026
CompletionActual
Mar 18, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06685185
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Nov 12, 2024
Primary completion
Mar 8, 2026
Completion
Mar 18, 2026
Last update
Apr 9, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion